1,4-dimethoxybenzene

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: No standard Draize test. Study not GLP, and no data on vehicle used.

Data source

Reference

Reference Type:

publication

Title:

The sensitization potential of some perfume ingredients tested using a modified Draize procedure.

Author:

Sharp DW

Year:

1978

Bibliographic source:

Toxicology, 9(3), 261-271.

Materials and methods

Principles of method if other than guideline:

Modified Draize test.

GLP compliance:

not specified

Type of study:

Draize test

Justification for non-LLNA method:

Study conducted prior to the recognition of the LLNA method as the preferred test method.

Test material

Test material information

Constituent 1

Reference substance name:

1,4-dimethoxybenzene

EC Number:

205-771-9

EC Name:

1,4-dimethoxybenzene

Cas Number:

150-78-7

Molecular formula:

C8H10O2

IUPAC Name:

1,4-dimethoxybenzene

Details on test material:

no data

In vivo test system

Test animals

Species:

guinea pig

Strain:

Hartley

Sex:

male/female

Details on test animals and environmental conditions:

TEST ANIMALS
- Source: Own colony of Unilever laboratory
- Age at study initiation: no data
- Weight at study initiation: 350 g
- Housing: in wire mesh cages in pair by sex
- Diet: guinea pig diet, cabbage and hay ad libitum
- Water: ad libitum
- Acclimation period: no data

ENVIRONMENTAL CONDITIONS: no data

IN-LIFE DATES: no data

Study design: in vivo (non-LLNA)

Induction

Induction 1

Route:

intradermal

Vehicle:

no data

Induction 2

Concentration / amount:

no data

Challenge

Challenge 1

Route:

intradermal and epicutaneous

Vehicle:

no data

Challenge 2

Concentration / amount:

no data

No. of animals per dose:

5 males and 5 females

Details on study design:

RANGE FINDING TESTS:
A preliminary study determined the ICC (injection challenge concentration), giving slight but perceptible irritation with no
oedema, 4 animals weighing 450 g (same sex) 0.1 ml injection intradermally, 0.1 ml of range of concentrations in solvent, examination of erythema
and oedema 24 h later.
The ACC (application challenge concentration), the highest concentration which caused no irritation. 4 animals weighing 450 g, 0.1 ml of
concentrations in solvent, applied 24 hours.

MAIN STUDY
A. INDUCTION EXPOSURE/DAY 0
- No. of exposures: 1
- SLS application: no
- Test groups: Test substance
- Control group: no
- Site: between the 2 auxillary and 2 inguinal lymph nodes
- Frequency of applications: 1 application in 4 intradermal injections.
- Duration: 14 days, day 0 to day 14
- Concentrations: 3%

Intradermal injection / day 0: administration onto 10 animals of 0.1 ml of the test substance at 3% by intradermal injection in 4 sites which overlie
the 2 auxillary and 2 inguinal lymph nodes.

B. CHALLENGE EXPOSURE
- No. of exposures: 2
- Day(s) of challenge: 14
- Test groups: ex: Test substance
- Control group: no
- Duration: 1 day
>Intradermal injection / day 14:
- Site: one flank
- Concentration: 0.2%(=ICC, Injection Challenge Control)
- exposure period: time of application
- Evaluation (hr after challenge): 24 h
0.1 ml of test substance was intradermally injected in one flank.

> Topical application / day 14:
- Site: the other flank
- Concentration: 50%(=ACC, Application Challenge Concentration)
0.1 ml of test substance was spread onto shaved flank in a small circular area which was not covered.
- exposure period: time of application
- Evaluation (hr after challenge): 24 h
24 hours after the challenge exposure, the reactions were scored and apparent sensitization reactions confirmed 7 days later by second challenge.

C. INDUCTION AND CHALLENGE REPEATED
INDUCTION EXPOSURE/DAY 21
- No. of exposures: 1
- SLS application: no
- Test groups: Test substance
- Control group: no
- Site: between the 2 auxillary and 2 inguinal lymph nodes
- Frequency of applications: 1 application in 4 intradermal injections.
- Duration: 14 days, day 21 to day 35
- Concentrations: 3%
Intradermal injections at 4 sites which overlie the 2 auxillary and 2 inguinal lymph nodes of 10 animals with test substance at concentration of 3%.

CHALLENGE / DAY 35
- No. of exposures: 2
- Day of challenge: 35
- Test groups: Test substance
- Control group: no

* Intradermal injection / day 35
- Site: one flank
- Concentration: 0.2%(=ICC, Injection Challenge Control)
- exposure period: time of application
- Evaluation (hr after challenge): 24 h
0.1 ml of test substance was intradermally injected in one flank.

* Topical application / day 35
- Site: the other flank
- Concentration: 50%(=ACC, Application Challenge Concentration)
0.1 ml of test substance was spread onto shaved flank in a small circular area which was not covered.
- exposure period: time of application
- Evaluation (hr after challenge): 24 h

D. RECHALLENGE / DAY 42
- No. of exposures: 2
- Day of challenge: 42
- Test groups: Test substance
- Control group: yes, 4 previously untreated animals.

* Intradermal injection / day 42
- Site: one flank
- Concentration: 0.2%(=ICC, Injection Challenge Control)
- exposure period: time of application
- Evaluation (hr after challenge): 24 h
0.1 ml of test substance was intradermally injected in one flank.

* Topical application / day 42
- Site: the other flank
- Concentration: 50%(=ACC, Application Challenge Concentration)
0.1 ml of test substance was spread onto shaved flank in a small circular area which was not covered.
- exposure period: time of application
- Evaluation (hr after challenge): 24 h

Challenge controls:

no

Positive control substance(s):

no

Results and discussion

In vivo (non-LLNA)

Results

Results 1

Reading:

rechallenge

Hours after challenge:

24

Group:

test chemical

Dose level:

0.1 ml at 50%

No. with + reactions:

0

Total no. in group:

10

Clinical observations:

none

Remarks on result:

other: Reading: rechallenge. . Hours after challenge: 24.0. Group: test group. Dose level: 0.1 ml at 50%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: none.

Results 2

Reading:

rechallenge

Group:

negative control

Dose level:

no data

Remarks on result:

other: No data

Results 3

Reading:

rechallenge

Group:

positive control

Dose level:

no data

Remarks on result:

other: No data

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

According to UN and EU GHS criterias, the substance is not classified for skin sensitization.

Executive summary:

In a dermal sensitization study (Sharp, 1978) with Paradimethoxybenzene, males and females Hartley guinea pigs  (5/sex) were tested in a modified Draize test. A 0.1 ml aliquot of test material, at 2.5 times the ICC, was injected intradermally at 4 sites which overlie the 2 auxiliary and 2 inguinal lymph nodes. The guinea pigs were challenged 14 days later by an intradermal injection of 0.1 ml test material into one flank and a topical open application of test material on the other flank at the respective injection challenge concentration (ICC) and application challenge concentration (ACC). Reactions were scored 24 hours after challenge treatments.

In absence of sensitization reactions, second induction and challenge procedures were repeated and a confirmatory challenge with controls was included. At each challenge with controls, 4 previously untreated animals of the same sex and similar weight to the test animals were treated intradermally and topically on opposite flanks with 0.1 ml aliquots of test substance at the ICC and ACC respectively. Reactions were examined under a Philips colour-matching unit. Each injection was given a total score based on size (2 largest diameters), erythema and oedema. Individual reactions were considered positive when their total score was significantly greater than the average total score for control reactions. 

No positive reaction were observed. In this study, Paradimethoxybenzene is not a skin sensitizer.